Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $32.00.
Several research analysts have commented on GRDN shares. Truist Financial lifted their price target on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Wall Street Zen raised shares of Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 17th. Oppenheimer began coverage on shares of Guardian Pharmacy Services in a research report on Friday, October 10th. They set an “outperform” rating and a $30.00 price target for the company. Finally, Stephens lifted their price objective on Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday.
View Our Latest Stock Report on Guardian Pharmacy Services
Institutional Trading of Guardian Pharmacy Services
Guardian Pharmacy Services Stock Down 8.7%
Shares of GRDN stock opened at $26.94 on Wednesday. The business has a 50-day moving average price of $29.95 and a two-hundred day moving average price of $26.43. Guardian Pharmacy Services has a 12-month low of $17.78 and a 12-month high of $37.43. The firm has a market cap of $1.71 billion, a P/E ratio of 42.75 and a beta of 0.96.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.01. The company had revenue of $377.43 million for the quarter, compared to analysts’ expectations of $381.16 million. Guardian Pharmacy Services had a return on equity of 30.29% and a net margin of 2.90%. As a group, research analysts expect that Guardian Pharmacy Services will post 0.87 EPS for the current fiscal year.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
See Also
- Five stocks we like better than Guardian Pharmacy Services
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
